Scholar Rock Holding: Pioneering Innovative Therapies for Serious Diseases and Patient Care

### Scholar Rock Advances Innovative Therapeutics for Serious Diseases

Scholar Rock Holding, a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on pioneering treatments for serious diseases, with a particular emphasis on spinal muscular atrophy (SMA) and cardiometabolic disorders. The company is recognized for its expertise in the transforming growth factor-beta (TGFβ) superfamily, which plays a crucial role in various biological processes. Scholar Rock develops novel monoclonal antibodies that selectively modulate these protein growth factors, aiming to unlock new therapeutic options in areas of high unmet medical need. This innovative approach represents a significant shift in how biopharmaceuticals address conditions that have been traditionally underserved by existing treatments.

Over the last decade, Scholar Rock has cultivated a robust pipeline that addresses various conditions, including neuromuscular diseases and cancer. The company’s commitment extends beyond merely developing drugs; it seeks to redefine care standards through its proprietary platform that emphasizes targeted therapies. By focusing on the selective modulation of growth factors, Scholar Rock aims to create more effective treatments that can improve patient outcomes and quality of life. This strategic direction positions the company as a leader in the biopharmaceutical industry, particularly in the realm of diseases that require advanced therapeutic approaches.

Looking ahead, Scholar Rock plans to provide updates on its progress and financial performance in an upcoming conference call scheduled for February 27, 2025. During this call, management will discuss the fourth quarter and full year 2024 financial results and provide a business update. Participants can register for the call and access a live audio webcast through the Scholar Rock website, with an archived version available for approximately 90 days post-event. This commitment to transparency reflects Scholar Rock’s dedication to engaging with its stakeholders while advancing its mission to develop life-changing therapies.

In addition to its focus on innovative treatments, Scholar Rock maintains a strong communication strategy, utilizing its website and social media channels to keep investors and the public informed about its advancements and ongoing projects. By leveraging these platforms, the company fosters a sense of community and transparency, ensuring stakeholders are well-informed about its research and development efforts. Scholar Rock's innovative approach and dedication to addressing critical health challenges underscore its role as a key player in the biopharmaceutical landscape.